With CoapTech, Steven Tropello and Howard Carolan are working on new technology for replacing patients’ feeding tubes.
The approach, called Percutaneous Ultrasound Gastrostomy, or PUG, utilizes a device with magnets that doctors can use to guide a feeding tube into place. It also features an ultrasound that allows doctors to see what is happening inside the body as the tube as it goes to the stomach, and identify the safest site for the tube to be placed.
It’s hard to get excited about a biotech shared-space in 2016.
Four years ago, it was an exciting and rapidly diversifying field. Now incubators are par for the course, with most Big Pharma and many institutions operating their own version.
Mass Innovation Labs was late to the game, opening in May 2015. But it is clearly doing something different.
Honoring those who see past the present to define the future
The future is not granted. It is born from the imagination of entrepreneurs. If you are a successful entrepreneur or have been inspired by an enterprising trailblazer, we’d like you to submit a nomination to the EY Entrepreneur Of The Year® 2017 program.
About the Entrepreneur Of The Year Program
Since 1986, EY has celebrated the accomplishments of thousands of entrepreneurs who have shaped the way we live, work and play. We recognize and honor these inspiring individuals through the Entrepreneur Of The Year.
Over three decades, the program has grown to span more than 145 cities, in more than 60 countries, and now boasts a roster of nearly 10,000 visionary trailblazers here in the US.
Despite a recent tapering of year-on-year growth, the global market for prescription drugs is forecast to reach $1.5 trillion per year by 2021, a 33 percent increase from 2016.
That’s according to a new report by the QuintilesIMS Institute, the research arm of the healthcare informatics company QuintilesIMS.
Ascension Ventures (AV) has finalized its latest strategic venture capital fund at $255 million. This fourth fund for AV, CHV IV, L.P., brings the firm’s total assets under management to more than $800 million. The new fund is backed by 13 health system partners, which enable AV to continue to add value to its portfolio companies while simultaneously delivering financial and strategic returns to the partners.
A defining moment in modern biology occurred on July 24, 1978, when biotechnology pioneer Robert Swanson, who had recently co-founded Genentech, brought two young scientists to dinner with Thomas Perkins, the legendary venture capitalist. As they stood outside Perkins’s magnificent mansion in Marin County, with its swimming pool and garden and a view of the Golden Gate Bridge, Swanson turned to his two young colleagues and said, “This is what we’re all working for.”
Inova announced today that Milton L. Brown, MD, PhD, has joined Inova where he will serve as director of the new Inova Center for Drug Discovery and Development and as deputy director for Drug Discovery for the Inova Schar Cancer Institute (ISCI). Dr. Brown is a physician scientist who has expertise in the design, synthesis, and evaluation of new drugs and is one of only a handful of physician scientists in the United States who hold a PhD in synthetic chemistry and an MD. He comes to Inova from Georgetown University Medical Center where he was founding director of the Drug Discovery Program (DDP).
Lingering for more than two years, the revamped 21st Century Cures bill, unveiled in late November, has now been approved by the House and Senate and President Barack Obama has said he will sign it.
The 996-page bill includes major tweaks to the way in which the US Food and Drug Administration (FDA) regulates drugs, devices and biologics, while providing the agency with $500 million over 10 years to implement provisions that seek to move such products to patients more quickly, while maintaining the same standard for safety and effectiveness that the agency has adhered to in the past.
Entrepreneurs can’t sit still for long.
Four months after announcing his departure from Google Ventures (now GV), which he cofounded and led, Bill Maris is reportedly raising a fresh $230 million VC fund that will focus on healthcare investments.
AbbVie (ABBV), a global biopharmaceutical company, and the Johns Hopkins University School of Medicine today announced that they signed a five-year collaboration agreement with the goal of advancing medical oncology research and discovery at both organizations.
Designed to build strong collaboration between AbbVie and Johns Hopkins Medicine researchers, the agreement will focus on several areas of oncology research, which could include lung, colorectal, breast, prostate and hematological cancer.
